What is the difference between USP and USP ?

USP General Chapter sets the general standards for sterile compounding of pharmaceuticals. USP General Chapter is the radiopharmaceutical-specific chapter that adapts those principles to the realities of radioactive drugs — short half-lives, unit-dose dispensing, generator elution, and the need for radiation shielding. Where applies, radiopharmaceutical handling follows rather than .

Radiopharmacy Aseptic Technique and QC

Q: How are radiopharmaceuticals tested for sterility if they decay so fast?

Short-lived radiopharmaceuticals are released for patient use before the 14-day sterility test (USP ) is complete, so sterility assurance relies on validated aseptic process, filter integrity, and end-product testing performed retrospectively. Endotoxin testing by the LAL method is rapid enough to be a true pre-release test. PET and generator products follow this released-before-results model with strong process controls.

Radiopharmacy aseptic technique and quality control are the linked practices that keep a radioactive drug both sterile and correctly characterized before it is injected — without exposing the people preparing it to unnecessary radiation. That dual mandate, sterility plus ALARA, is what makes radiopharmacy different from ordinary sterile compounding.

A radiopharmaceutical is a parenteral drug, so it must meet the same patient-protection bar as any injectable: sterile, non-pyrogenic, and accurately prepared. But it is also a short-lived, often high-activity radioactive material that is dispensed under time pressure and shielding constraints. The program that reconciles those two demands is built on USP General Chapters <825>, <797>, and <823>, on validated aseptic process, and on a defined panel of release tests.¹²⁵⁶

Introduction

In most pharmacies, the compounding clock is forgiving. In a radiopharmacy it is not: an F-18 product loses about half its activity every 110 minutes, a Ga-68 product every 68 minutes, and a generator eluate must be used quickly. Doses are frequently released for patient injection before the 14-day sterility test can possibly finish.⁶⁸ That reality forces radiopharmacy to lean heavily on process assurance — validated aseptic technique, engineering controls, and competency testing — rather than on waiting for a final sterility result.

At the same time, the operator is handling activity that drives meaningful hand and body dose. Lead glass, syringe and vial shields, tongs, and speed all reduce dose but can work against clean aseptic manipulation. The art of radiopharmacy is keeping both curves down at once: contamination risk and radiation dose.

This guide explains aseptic technique and QC in the radiopharmacy: the governing USP framework, the engineering controls and competency tests, the release-test panel and its acceptance criteria, the clinical impact, practical tips, and the regulatory overlay. DRPS supports nuclear pharmacies and nuclear medicine departments through its PET/CT and nuclear medicine physics and radiation safety officer services across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware.

Topic Explanation

The USP framework: <797>, <825>, and <823>

Three USP General Chapters define the sterile-handling expectations for radioactive drugs, and knowing which one governs is the first compliance step.

USP <797>, Pharmaceutical Compounding — Sterile Preparations is the general sterile-compounding chapter (current revision official November 1, 2023). It sets the baseline concepts: garbing, ISO-classified air, beyond-use dating, and competency testing.²
USP <825>, Radiopharmaceuticals — Preparation, Compounding, Dispensing, and Repackaging is the radiopharmaceutical-specific chapter (official December 1, 2020). It adapts sterile-compounding principles to radioactive realities: shielding, generator elution, unit-dose dispensing, decay, and the engineering environments — segregated radiopharmaceutical processing areas, ambient/hot lab arrangements, and cleanroom suites — appropriate to nuclear pharmacy.¹⁶
USP <823>, Radiopharmaceuticals for Positron Emission Tomography — Compounding addresses PET drug compounding, bridging investigational and clinical PET production.⁵

Where <825> applies, radiopharmaceutical handling follows <825> rather than being forced into the general <797> mold — the chapter exists precisely because nuclear medicine professionals needed standards built around radioactive drugs.⁶

Sterile, nonsterile, and "released before results"

A radiopharmaceutical injection must be sterile and non-pyrogenic, but the short half-life means the standard 14-day sterility test (USP <71>) finishes long after the dose has decayed and been administered.⁴⁸ Radiopharmacy therefore operates on a released-before-results model: the dose is released on the strength of validated aseptic process, filter-integrity checks, appearance, pH, and a rapid endotoxin test, while the sterility test runs retrospectively as a process monitor.⁶⁸ This is why aseptic technique and process validation carry so much weight — they are the real-time sterility assurance.

For the radiochemistry side of release testing, see our companion guide to radiochemical purity and TLC quality control.

Key Technical Principles

Engineering controls and ISO air classes

Sterile compounding occurs in a primary engineering control (PEC) that provides ISO Class 5 air — a laminar-airflow workbench or biological safety cabinet — usually situated within a cleaner supporting room. Air-cleanliness classes are defined by ISO 14644-1 in terms of the maximum allowed concentration of airborne particles per cubic meter.¹¹ ISO Class 5 permits no more than 3,520 particles ≥0.5 µm per cubic meter; the supporting ISO Class 7 environment permits up to 352,000 per cubic meter.

ISO class	Max particles ≥0.5 µm/m³	Legacy "class"	Typical radiopharmacy use
ISO Class 5	3,520	Class 100	Primary engineering control (LAFW/BSC) for sterile manipulation
ISO Class 7	352,000	Class 10,000	Buffer/cleanroom around the PEC
ISO Class 8	3,520,000	Class 100,000	Ante-area / supporting space

The radiopharmacy twist is that the PEC must also accommodate shielding (L-blocks, lead glass, shielded syringes and vials), which can disturb the unidirectional "first air" that keeps the critical site sterile. Designing the workspace so shielding does not block first air to the needle, vial septum, and syringe tip is a core aseptic-engineering problem unique to nuclear pharmacy.¹⁶

Aseptic technique and competency verification

Aseptic technique is verified, not assumed. Two competency tests anchor the program:²⁶

Gloved fingertip testing — after garbing, the operator's gloved fingertips are sampled onto growth media to confirm hand-hygiene and garbing competency.
Media-fill testing — an aseptic-process simulation in which sterile growth medium is manipulated exactly as a real preparation, then incubated. Growth indicates a process or operator failure.

These are paired with surface disinfection (e.g., sterile 70% isopropyl alcohol), validated hand hygiene and garbing, and no-touch manipulation of critical sites within first air.

That the technique works in practice is supported by data: a benchmark study of 1,516 radiopharmaceutical samples compounded across seven commercial nuclear pharmacies found microbial growth in only 0.86% of samples and bacterial-endotoxin gel-clot positivity in only 0.27% — evidence that disciplined aseptic compounding yields very low contamination rates.⁷

Bacterial endotoxin limits

Even a sterile product can be pyrogenic if it carries bacterial endotoxin. USP <85> sets the limit by the formula:

E L = \frac{K}{M}

where $E L$ is the endotoxin limit, $K$ is the threshold pyrogenic dose, and $M$ is the maximum recommended human dose per kilogram administered in a single hour. For radiopharmaceuticals, USP expresses this in a dose-volume form: the limit is 175 EU per V for non-intrathecal administration and 14 EU per V for intrathecal administration, where $V$ is the maximum recommended total dose in milliliters at expiry.³

Worked example. Consider an F-18 FDG preparation with a maximum recommended administered volume of $V = 10$ mL at end of synthesis. The endotoxin concentration limit is:

E L = \frac{175 EU}{V} = \frac{175 EU}{10 mL} = 17.5 EU/mL

A measured endotoxin content below 17.5 EU/mL would pass — consistent with published Ga-68 and F-18 validation work reporting endotoxin results well under that ceiling (for example, <17.5 EU/mL for a Ga-68 DOTATATE validation).³⁸ Because the LAL (limulus amebocyte lysate) endotoxin assay can be completed in well under an hour, it is one of the few microbiological tests fast enough to be a true pre-release test for short-lived products.⁸⁹

The release-test panel

A radiopharmaceutical is released against a defined panel that spans pharmacy and radiochemistry. Typical elements and their roles:

QC test	Method (example)	Purpose / typical criterion
Visual appearance	Visual inspection (behind shielding)	Clear, particle-free, correct color
pH	pH strip / meter	Within product specification
Radiochemical purity	TLC / HPLC	Fraction in desired chemical form above product limit (e.g., ≥95%)
Radionuclidic purity	Gamma spectroscopy; generator breakthrough	Correct radionuclide; Mo-99/Ge-68 breakthrough below limit
Filter integrity	Bubble-point test	Sterilizing filter intact (post-filtration)
Bacterial endotoxin	LAL assay	≤175/V EU/mL (non-intrathecal) ³
Sterility	Membrane filtration / direct inoculation (USP <71>)	No growth at 14 days (retrospective) ⁴

Published validation studies illustrate the panel in action: Ga-68 DOTATATE,⁸ Ga-68 PSMA-11,⁹ and F-18 PET tracers¹⁰ are each released only after appearance, pH, radiochemical and radionuclidic purity, filter integrity, endotoxin, and sterility testing are specified and met. For the generator-breakthrough side, see our guide to Tc-99m generator quality control.

Clinical Impact

The clinical purpose of radiopharmacy aseptic technique and QC is to guarantee that what reaches the patient is sterile, non-pyrogenic, correctly identified, and accurately measured — every time. The failure modes are serious:

Microbial contamination of an injectable can cause bloodstream infection. Sterile-compounding failures in pharmacy generally have caused fatal outbreaks, which is part of why USP tightened these standards.²
Endotoxin (pyrogen) contamination can cause febrile reactions even when the product is sterile, which is why endotoxin is tested independently of sterility.³
Radiochemical or radionuclidic impurity degrades image quality, can cause unexpected biodistribution, and — in the case of generator breakthrough — delivers unintended dose from a long-lived contaminant.⁸
Dose-measurement error at the dose calibrator translates directly into wrong administered activity; see dose calibrator quality control.

The ALARA dimension is clinical too: a workflow that protects sterility but soaks the technologist's hands in dose is not acceptable, and one that minimizes dose by rushing or skipping aseptic steps is not acceptable either. The program has to hold both.

Practical Optimization Tips

1. Design the PEC around first air and shielding

Position shields so they protect the operator without blocking unidirectional first air to the needle, vial septum, and syringe tip. Validate the actual configuration, not an idealized empty hood.¹⁶

2. Make competency testing routine and documented

Gloved fingertip and media-fill testing are not one-time hurdles. Schedule them, document them, and re-test after any failure or process change. These records are the backbone of "released-before-results" defensibility.²⁶

3. Treat endotoxin testing as a real release gate

Because LAL is fast, build it into the release workflow rather than treating it as paperwork. Confirm the limit calculation (175/V or 14/V) for each product's maximum dose volume.³

4. Separate the radiation-safety and sterility roles, then integrate them

The RSO owns contamination/exposure controls; the authorized nuclear pharmacist owns sterility and release. They share a bench. Build SOPs that make the safe, sterile action the same action — e.g., closed-system transfer devices, single-use sterile supplies, and disinfection steps that also support contamination surveys. See nuclear medicine decontamination best practices.

5. Trend, don't just record

Track gloved-fingertip failures, media-fill failures, endotoxin results, and environmental monitoring over time. A drift is a warning before it becomes an event.⁷

Common pitfalls

Letting shielding block first air to the critical site.
Treating the 14-day sterility test as the sterility assurance instead of recognizing it is retrospective for short-lived products.⁸
Skipping or back-dating competency tests when staffing is tight.
Miscalculating the endotoxin limit by using the wrong maximum dose volume.³
Letting ALARA and aseptic goals fight instead of engineering SOPs that satisfy both.

Regulatory Considerations

Radiopharmacy is governed by an overlap of pharmacy, radioactive-material, and FDA authorities, and a compliant program reconciles all of them.

USP General Chapters <825>, <797>, <823>, <85>, and <71> establish the compounding, sterility, and endotoxin standards. State boards of pharmacy frequently adopt USP chapters by reference, which is how they become enforceable.¹²³⁴⁵⁶
FDA 21 CFR Part 212 sets current good manufacturing practice (cGMP) for PET drugs produced under an approved application or registration, distinct from compounding under USP <823>.¹²
NRC / Agreement State radioactive-material rules (10 CFR Parts 20 and 35, or the state equivalent) govern the radiation-safety overlay — possession, surveys, waste, and worker dose. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States, while Washington DC and Delaware are regulated directly by the NRC for byproduct material. Confirm which authority issues your license and which rules apply.

The practical compliance task is harmonizing these into one set of SOPs so that an inspector from any of them sees a consistent, documented program. The continuing-education literature aimed at nuclear medicine technologists is explicit that USP <825> gives nuclear pharmacies and departments concrete benchmarks to assess current practice and prepare for regulatory and accreditation review.⁶ For broader license context, see our NRC radioactive material license guide.

Frequently Asked Questions (FAQs)

What is aseptic technique in a radiopharmacy?

Aseptic technique is the set of practices and engineering controls that keep a radiopharmaceutical sterile during preparation, compounding, and dispensing — hand hygiene and garbing, working in an ISO Class 5 primary engineering control, proper first-air and no-touch manipulation of critical sites, surface disinfection, and competency verification through gloved fingertip and media-fill testing. In a radiopharmacy it must be achieved while keeping operator radiation dose as low as reasonably achievable.

What is the difference between USP <825> and USP <797>?

USP <797> sets general standards for sterile compounding. USP <825> is the radiopharmaceutical-specific chapter that adapts those principles to radioactive drugs — short half-lives, unit-dose dispensing, generator elution, and shielding. Where <825> applies, radiopharmaceutical handling follows <825> rather than <797>.

What is the bacterial endotoxin limit for radiopharmaceuticals?

Under USP <85>, the endotoxin limit for a non-intrathecally administered radiopharmaceutical is 175 EU divided by V, where V is the maximum recommended total dose in milliliters at expiry; for intrathecal administration the limit is 14 EU divided by V. For example, an F-18 FDG product with a 10 mL maximum dose would have a limit of 17.5 EU/mL.

How are radiopharmaceuticals tested for sterility if they decay so fast?

Short-lived products are released before the 14-day sterility test (USP <71>) is complete, so sterility assurance relies on validated aseptic process, filter integrity, and end-product testing performed retrospectively. The LAL endotoxin test is rapid enough to be a true pre-release test. PET and generator products follow this released-before-results model with strong process controls.

What is media-fill testing?

Media-fill testing is an aseptic-process simulation in which sterile growth medium is manipulated exactly as a real preparation would be, then incubated to see whether any units become contaminated. It validates that the operator and process can produce a sterile product, and is paired with gloved fingertip sampling to verify garbing and hand-hygiene competency.

What cleanroom classification does a radiopharmacy need?

Sterile compounding is performed in an ISO Class 5 primary engineering control such as a laminar-airflow or biological safety cabinet, typically within an ISO Class 7 or ISO Class 8 supporting environment depending on the operation and the controls in USP <825>. Air-cleanliness classes are defined by ISO 14644-1 according to airborne particle concentration.

Who is responsible for radiopharmacy QC and aseptic compliance?

Accountability is shared: the authorized nuclear pharmacist or authorized user oversees compounding and release, the RSO oversees the radiation-safety overlay, and a qualified medical physicist supports instrument QC and program review. State boards of pharmacy, the NRC or Agreement State, and accreditation bodies all set requirements that must be reconciled into one program.

Key Takeaways

Radiopharmacy must keep doses sterile and keep operator dose low — the defining tension of the field.¹⁶
USP <825> is the radiopharmaceutical-specific chapter; <797> is the general sterile baseline and <823> covers PET compounding. Know which governs.¹²⁵
Short half-lives force a released-before-results model, so validated aseptic process and competency testing are the real-time sterility assurance.⁶⁸
Endotoxin is tested separately from sterility, with a 175/V EU/mL limit (14/V intrathecal); the fast LAL assay makes it a true release gate.³
Disciplined aseptic technique works — benchmark contamination rates in commercial nuclear pharmacies are well under 1%.⁷
Compliance means harmonizing pharmacy, NRC/Agreement State, and FDA requirements into one documented program.

Conclusion

Radiopharmacy aseptic technique and QC are where patient safety and radiation safety meet on the same bench. The drug must be sterile and non-pyrogenic like any injectable, yet it is radioactive, short-lived, and dispensed under shielding and time pressure. The modern framework — USP <825> built on <797> and <823>, validated aseptic process, competency testing, and a defined release panel anchored by rapid endotoxin testing — is what lets a radiopharmacy release a dose for injection before its sterility result is even available, with confidence that it is safe.¹²⁶⁸

Done well, the program is invisible: sterile doses, low staff dose, clean inspections. Done poorly, it is the source of the rare but serious events that the standards exist to prevent. The difference is disciplined technique, honest competency testing, and a program that treats sterility and ALARA as one problem, not two.

How DRPS Can Help

Diagnostic Radiation Physics Services helps nuclear pharmacies and nuclear medicine departments build and audit the QC and radiation-safety side of radiopharmaceutical handling: instrument QC for dose calibrators and survey instruments, environmental and contamination monitoring program design, release-panel and SOP review, and reconciliation of USP, NRC/Agreement State, and FDA expectations into one defensible program. This is delivered through our PET/CT and nuclear medicine physics, radiation safety officer, and radioactive material license support services.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A strong radiopharmacy program makes the sterile, low-dose action the routine action — so the safe dose is the easy dose.

Related Resources

References

United States Pharmacopeia. General Chapter <825> Radiopharmaceuticals — Preparation, Compounding, Dispensing, and Repackaging. Official December 1, 2020. usp.org
United States Pharmacopeia. General Chapter <797> Pharmaceutical Compounding — Sterile Preparations. Official November 1, 2023. usp.org
United States Pharmacopeia. General Chapter <85> Bacterial Endotoxins Test. usp.org
United States Pharmacopeia. General Chapter <71> Sterility Tests. usp.org
United States Pharmacopeia. General Chapter <823> Radiopharmaceuticals for Positron Emission Tomography — Compounding. usp.org
Hinkle GH. USP General Chapter <825> impact on nuclear medicine technology practice. J Nucl Med Technol. 2020;48(2):106-113. doi:10.2967/jnmt.120.243378. doi.org
Weatherman KD, Augustine S, Christoff J, Galbraith W. Establishing benchmark rates of microbial and bacterial endotoxin contamination for radiopharmaceuticals compounded in commercial nuclear pharmacy settings. Int J Pharm Compd. 2013;17(2):168-174. PubMed
Sammartano A, Migliari S, Scarlattei M, Baldari G, Ruffini L. Validation of quality control parameters of cassette-based gallium-68-DOTA-Tyr3-octreotate synthesis. Indian J Nucl Med. 2020;35(4):291-298. doi:10.4103/ijnm.IJNM_66_20. doi.org
Rodnick ME, Sollert C, Stark D, et al. Synthesis of 68Ga-radiopharmaceuticals using both generator-derived and cyclotron-produced 68Ga as exemplified by [68Ga]Ga-PSMA-11 for prostate cancer PET imaging. Nat Protoc. 2022;17(4):980-1003. doi:10.1038/s41596-021-00662-7. doi.org
Jahan M, Amir A, Das A, Kihlström J, Nag S. Automated radiosynthesis of mGluR5 PET tracer [18F]FPEB from aryl-chloro precursor and validation for clinical application. J Labelled Comp Radiopharm. 2024;67(4):155-164. doi:10.1002/jlcr.4088. doi.org
International Organization for Standardization. ISO 14644-1:2015 Cleanrooms and associated controlled environments — Part 1: Classification of air cleanliness by particle concentration. iso.org
U.S. Food and Drug Administration. 21 CFR Part 212 — Current Good Manufacturing Practice for Positron Emission Tomography Drugs. ecfr.gov